根治性局部治疗与转移性宫颈癌总生存改善相关
基于美国国家癌症数据库2838例新诊断转移性宫颈癌化疗患者,1194例(42%)接受根治性局部治疗、1644例(58%)接受保守治疗。倾向评分加权Cox模型显示根治性局部治疗与总生存改善相关(HR 0.57,95%CI 0.52-0.62,P≤.001),中位总生存19.2个月 vs 10.1个月。
要点
- 根治性局部治疗组中位总生存19.2个月,保守治疗组10.1个月。
- 倾向评分加权后根治性局部治疗与总生存改善相关(HR 0.57,95%CI 0.52-0.62,P≤.001)。
- 生存至少12个月患者的界标分析结果一致(HR 0.71,95%CI 0.62-0.82,P≤.001)。
核心结论
- 根治性局部治疗与转移性宫颈癌患者总生存改善相关,作者认为这提示了根治性局部治疗在转移性病变中的新应用场景。
研究设计与样本
- 从美国国家癌症数据库纳入年龄≥18岁、新诊断转移性宫颈癌且接受化疗的患者共2838例。
- 按治疗方式分为根治性局部治疗组(同步放化疗或根治性手术)1194例(42%)与保守治疗组(全身治疗伴或不伴姑息性放疗)1644例(58%)。
- 采用倾向评分加权Cox比例风险模型评估根治性局部治疗与总生存的关联,并通过敏感性分析评估潜在未测量混杂。
- 采用多因素logistic回归识别与接受根治性局部治疗相关的因素。
主要发现
- 接受根治性局部治疗与合并症较少、临床T分期较低及淋巴结阴性病变在统计学上显著相关。
- 与保守治疗相比,根治性局部治疗与总生存改善相关(HR 0.57,95%CI 0.52-0.62,P≤.001)。
- 根治性局部治疗组中位总生存为19.2个月,保守治疗组为10.1个月。
- 上述结果在敏感性分析中及对生存至少12个月患者的界标分析中均稳健(HR 0.71,95%CI 0.62-0.82,P≤.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Definitive local therapy is often used in metastatic cervical cancer to reduce morbidity associated with local tumor progression. However, the potential benefit of this therapeutic approach has not been rigorously investigated. We hypothesized that definitive local therapy is associated with improved overall survival (OS) in metastatic cervical cancer. METHODS AND MATERIALS: Patients aged ≥18 years with newly diagnosed metastatic cervical cancer who were treated with chemotherapy were identified from the National Cancer Database. Patients were dichotomized into the following cohorts: definitive local therapy (defined as either concurrent chemoradiation therapy or definitive surgery) or conservative therapy (defined as systemic therapy with or without palliative radiation therapy). The association between definitive local therapy and OS was assessed using propensity score-weighted Cox proportional hazards models. Potential unmeasured confounding was assessed through sensitivity analyses. Factors associated with the receipt of definitive local therapy were identified with multivariable logistic regression. RESULTS: A total of 2838 patients were identified, of whom 1194 (42%) and 1644 (58%) were treated with definitive local and conservative therapy, respectively. Receipt of definitive local therapy was statistically significant, associated with less comorbidity, lower clinical T stage, and node negative disease. Compared with conservative therapy, definitive local therapy was associated with improved OS (hazard ratio: 0.57; 95% confidence interval, 0.52-0.62; P ≤ .001). The median OS rate was 19.2 months in the definitive local therapy cohort and 10.1 months in the conservative therapy cohort. These findings were robust to potential unmeasured confounding in sensitivity analyses and on landmark analyses of patients who survived at least 12 months (hazard ratio: 0.71; 95% confidence interval, 0.62-0.82; P ≤ .001). CONCLUSIONS: Definitive local therapy is associated with improved OS in patients with metastatic cervical cancer. These findings suggest a novel setting for the use of definitive local therapy in the metastatic setting.
引用
- Venigalla S, Guttmann DM, Horne ZD, et al. Definitive local therapy is associated with improved overall survival in metastatic cervical cancer. Pract Radiat Oncol. 2018. PMID: 30174248. doi:10.1016/j.prro.2018.05.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。